Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | 8.5 | 16.1 | 12.2 | 13.1 | 14.2 | 14.3 | 16.9 | 18.7 |
| Operating profit | $bn | 3.58 | 4.99 | ||||||
| Net profit | $bn | 3.51 | 8.08 | 4.34 | 3.95 | 4.41 | 4.50 | 4.82 | 7.39 |
| EPS reported | $ | 41.48 | 45.26 | ||||||
| Operating cashflow per share | $ | 47.60 | 47.65 | ||||||
| Capex per share | $ | 8.59 | 10.03 | ||||||
| FCF per share | $ | 39.01 | 37.62 | ||||||
| Free cash flow | $bn | 4.08 | 3.83 | ||||||
| Net debt | $bn | -6.62 | -7.31 | ||||||
| Book value equity | $bn | 31.3 | 33.5 | ||||||
| Book value per share | $ | 287.8 | 317.2 | ||||||
| Number of shares | m | 108.6 | 105.6 | ||||||
| DPS (TTM paid) | $ | 3.52 | 3.70 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 18.61 | 21.20 | ||||||
| P/B LTM | x | 2.58 | 2.96 | ||||||
| P/S LTM | x | 5.63 | 5.87 | ||||||
| P/FCF LTM | x | 19.79 | 25.93 | ||||||
| EV/EBITDA LTM | x | 13.81 | 14.72 | ||||||
| EV/Sales LTM | x | 5.60 | 5.44 | ||||||
| Earnings Yield LTM | % | 5.37% | 4.72% | ||||||
| FCF Yield | % | 5.05% | 3.86% | ||||||
| Quality | |||||||||
| ROE | % | 14.41% | 15.07% | ||||||
| ROIC | % | 8.51% | 10.86% | ||||||
| Operating margin | % | 24.95% | 29.54% | ||||||
| Gross margin | % | 85.35% | 85.77% | ||||||
| FCF/Sales | % | 28.45% | 22.65% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +8.19% | +8.38% | ||||||
| Sales Growth YoY | % | +0.99% | +18.59% | ||||||
| Net Income Growth YoY | % | +2.09% | +5.23% | ||||||
| FCF Growth | % | +11.35% | -7.90% | ||||||
| Operating Profit Growth | % | -10.34% | +35.34% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.46% | 0.39% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 8.22% | 7.92% | ||||||
| FCF/Debt | x | 1.51 | 1.41 | ||||||
| Net Debt/EBITDA | x | -0.07 | -0.15 | ||||||
| EBIT/Net interest | x | 81.69 | 106.88 | ||||||
| Net debt/market cap | % | -8.20% | -7.37% | ||||||
| Net debt/Equity | x | -0.21 | -0.22 | ||||||
| Gross debt/equity | x | 0.09 | 0.08 | ||||||
ETFs that hold Regeneron Pharmaceuticals
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Biotechnology ETF | IBB | 5 | 6.19% |
| State Street SPDR S&P Biotech ETF | XBI | 8 | 1.70% |
| First Trust NYSE Arca Biotechnology Index Fund | FBT | 3 | 4.03% |
| First Trust Nasdaq-100 Select Equal Weight ETF | QQEW | 4 | 2.57% |
| Harvest Healthcare Leaders Income ETF | HHL.TO | 1 | 5.41% |
| iShares Nasdaq US Biotechnology UCITS ETF | BTEC.L | 5 | 5.99% |
| iShares Morningstar Mid-Cap Value ETF | IMCV | 8 | 1.24% |
| First Trust Nasdaq Pharmaceuticals ETF | FTXH | 9 | 3.86% |
| First Trust Health Care AlphaDEX Fund | FXH | 8 | 2.17% |
| iShares Ageing Population UCITS ETF | AGED.L | 5 | 0.70% |
Funds with Regeneron Pharmaceuticals among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Regeneron Pharmaceuticals, Inc. (REGN)
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| iShares Biotechnology ETF | IBB | 5 | 6.19% |
| State Street SPDR S&P Biotech ETF | XBI | 8 | 1.70% |
| First Trust NYSE Arca Biotechnology Index Fund | FBT | 3 | 4.03% |
| First Trust Nasdaq-100 Select Equal Weight ETF | QQEW | 4 | 2.57% |
| Harvest Healthcare Leaders Income ETF | HHL.TO | 1 | 5.41% |
| iShares Nasdaq US Biotechnology UCITS ETF | BTEC.L | 5 | 5.99% |
| iShares Morningstar Mid-Cap Value ETF | IMCV | 8 | 1.24% |
| First Trust Nasdaq Pharmaceuticals ETF | FTXH | 9 | 3.86% |
| First Trust Health Care AlphaDEX Fund | FXH | 8 | 2.17% |
| iShares Ageing Population UCITS ETF | AGED.L | 5 | 0.70% |
Funds with Regeneron Pharmaceuticals among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free